Payment overview · 2025
General Payments
$439.92
21 reported records · 9 companies
Healthcare provider profile · identity verified
Irina Chteingardt, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MAYFIELD HTS, OH · NPI 1376563734
Verified facts
What the public records show
CMS Open Payments records show Irina Chteingardt, MD received $439.92 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.51 | 38.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.60 | 12.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.86 | 11.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.61 | 9.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.50 | 8.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.70 | 7.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.27 | 6.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.67 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.20 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.92 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.02 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.15 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.60 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.60 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 431 | 127 |
| Tramadol Hcl | Tramadol Hcl | 358 | 76 |
| Gabapentin | Gabapentin | 357 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 103 |
| Metoprolol Tartrate | Metoprolol Tartrate | 345 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 75 |
| Losartan Potassium | Losartan Potassium | 275 | 70 |
| Potassium Chloride | Potassium Chloride | 220 | 66 |
| Furosemide | Furosemide | 211 | 63 |
| Metformin Hcl | Metformin Hcl | 201 | 55 |
| Eliquis | Apixaban | 197 | 50 |
| Lisinopril | Lisinopril | 197 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 46 |
| Trazodone Hcl | Trazodone Hcl | 180 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 34 |
| Omeprazole | Omeprazole | 148 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 143 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 38 |
| Carvedilol | Carvedilol | 128 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 43 |
| Montelukast Sodium | Montelukast Sodium | 106 | 27 |
| Simvastatin | Simvastatin | 102 | 26 |
| Prednisone | Prednisone | 98 | 58 |
| Allopurinol | Allopurinol | 94 | 25 |
| Glimepiride | Glimepiride | 92 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 27 |
| Memantine Hcl | Memantine Hcl | 80 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 20 |
| Glipizide | Glipizide | 75 | 15 |
| Alprazolam | Alprazolam | 72 | 17 |
| Buspirone Hcl | Buspirone Hcl | 70 | 17 |
| Ibuprofen | Ibuprofen | 69 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 23 |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Mirtazapine | Mirtazapine | 62 | 16 |
| Cefuroxime | Cefuroxime Axetil | 61 | 53 |
| Azithromycin | Azithromycin | 60 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 16 |
| Alendronate Sodium | Alendronate Sodium | 59 | 18 |
| Nystatin | Nystatin | 56 | 14 |
| Torsemide | Torsemide | 54 | 20 |
| Farxiga | Dapagliflozin Propanediol | 52 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 16 |
| Metformin Hcl Er | Metformin Hcl | 50 | 16 |
| Spironolactone | Spironolactone | 49 | 19 |
| Hydrocortisone | Hydrocortisone | 48 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Lorazepam | Lorazepam | 47 | 13 |
| Meloxicam | Meloxicam | 47 | 13 |
| Atenolol | Atenolol | 45 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 11 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Jardiance | Empagliflozin | 41 | 13 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 15 |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Finasteride | Finasteride | 36 | 13 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Digoxin | Digoxin | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 11 |
| Klor-Con M10 | Potassium Chloride | 27 | 12 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Celecoxib | Celecoxib | 24 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Colchicine | Colchicine | 23 | 11 |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 15 |
| Ramipril | Ramipril | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 11 |
| Estradiol | Estradiol | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.92 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, OFEV, OTEZLA, REPATHA, TZIELD, VERQUVO, VOQUEZNA, VRAYLAR, VYNDAQEL | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error